AstraZeneca sets ambition to deliver $80 billion Total Revenue by …
May 21, 2024 · Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade.
AstraZeneca - Research-Based BioPharmaceutical Company
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States. 12 November 2024. Corporate Press Release. Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial. 12 November 2024.
Media Centre - AstraZeneca
Oct 21, 2024 · Medical releases. AstraZeneca Media centre. The Hub for our Articles, Press Releases and Webcasts & Presentations.
AstraZeneca to acquire Fusion to accelerate the development of …
Mar 19, 2024 · AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing ...
AstraZeneca China President currently under investigation
Oct 30, 2024 · Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities. Our China operations continue under the leadership of the current General Manager of AstraZeneca China.
Q1 2024 results - AstraZeneca
Apr 25, 2024 · “AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter. Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer, the data from both of these studies will be presented during the ASCO ...
Calquence combination regimen demonstrated statistically
May 2, 2024 · Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard ...
COVID-19 Vaccine AstraZeneca confirms 100% protection against …
Feb 3, 2021 · The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose. Results demonstrated vaccine efficacy of 76% ...
Full Year and Q4 2023 results - AstraZeneca
Feb 8, 2024 · We expect another year of strong growth in 2024, driven by continued adoption of our medicines across geographies. Our differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to deliver industry-leading growth.”.
Pipeline - AstraZeneca
AstraZeneca’s deep pipeline of medicines focusing on their key therapeutic areas.
- Some results have been removed